Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis
Chad A. Newton(The University of Texas Southwestern Medical Center), Christine Kim Garcia(NewYork–Presbyterian Hospital), Ganesh Raghu(University of Washington), Julia Kozlitina(Southwestern Medical Center), Shwu‐Fan Ma(University of Chicago), David Zhang(Molina Center for Energy and the Environment), Imre Noth(University of Virginia), Fernando J. Martínez(University of Massachusetts Chan Medical School), Justin M. Oldham(Michigan Medicine)
American Journal of Respiratory and Critical Care Medicine
December 19, 2018
Cited by 166
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k